Olema Pharmaceuticals, Inc. (OLMA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Francisco, CA, United States. The current CEO is Sean Bohen.
OLMA has IPO date of 2020-11-19, 96 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.42B.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
